Triple treatment for cervical Ca shows great promise
Adding hyperthermia to standard chemoradiotherapy for advanced cervical carcinoma seems to boost the positive effects of treatment without adding any negative effects, according to analysis of three phase 2 studies.
Adding hyperthermia to standard chemoradiotherapy for advanced cervical carcinoma seems to boost the positive effects of treatment without adding any negative effects, according to analysis of three phase 2 studies.
Most of 68 women with a median age of 45 years and stage IIB, III, or IVA disease received a biologically effective radiotherapy and brachytherapy dose of 86.7 gray or higher, at least four courses of 40 mg/m2 weekly cisplatin, and four weekly sessions of locoregional hyperthermia.
Ninety percent of the women achieved complete remission. After a median of 18 months, 84% of the women remained alive, 74% of whom were without recurrence. Toxicity was comparable to that with chemoradiotherapy alone. A phase 3 study of the triple treatment is underway.
Newsletter
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Trimethoprim–sulfamethoxazole not found to increase infant birth weight in HIV cases
July 9th 2025A recent randomized trial found no significant improvement in birth weight or key birth outcomes from antenatal trimethoprim–sulfamethoxazole prophylaxis in human immunodeficiency virus-positive pregnant women.
Read More
